Go Deep
AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,238 | -3.4 | 1.79 | 0.00 | 342.84 |
| Oct 2026 | 21,294 | -3.4 | 1.76 | 0.00 | 336.11 |
| Oct 2026 | 21,238 | -3.5 | 1.79 | 0.00 | 341.86 |
| Oct 2026 | 21,446 | -3.2 | 1.68 | 0.00 | 320.14 |
| Oct 2026 | 21,455 | -3.2 | 1.68 | 0.00 | 319.53 |
| Oct 2026 | 21,276 | -3.4 | 1.77 | 0.00 | 337.55 |
| Oct 2026 | 21,238 | -3.4 | 1.79 | 0.00 | 340.50 |
| Oct 2026 | 21,200 | -3.5 | 1.81 | 0.00 | 343.58 |
AN2 Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -8,185,000.0 | -10,028,000.0 | -8,710,000.0 | -9,353,000.0 |
| EPS | -0.2 | -0.3 | -0.3 | -0.3 |
AN2 Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -35,174,000.0 | -51,321,000.0 | -64,732,000.0 | -40,956,000.0 | — |
| EPS | -1.2 | -1.7 | -2.7 | -2.8 | — |
AN2 Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 61,950,000.0 | 92,087,000.0 | 138,744,000.0 | 102,560,000.0 | — |
| Total Liabilities | 8,890,000.0 | 10,238,000.0 | 14,043,000.0 | 7,188,000.0 | — |
| Total Equity | 53,060,000.0 | 81,849,000.0 | 124,701,000.0 | 95,372,000.0 | — |
Owes vs Owns
AN2 Therapeutics, Inc. owed $0.07 for every $1 it owned in Jun 2026, about the same as $0.07 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.07× | 0.14× | 0.11× | 0.10× | 0.07× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
AN2 Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 93.6%Long-term investments 3.2%Other assets 3.1%
How it's funded — Dec 2025
Payables 4.9%Other liabilities 9.5%Shareholders' equity 85.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 58.0 | 83.6 | 107.3 | 96.1 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 2.0 | 5.0 | 27.2 | 3.2 |
| Other assets | 1.9 | 3.4 | 4.3 | 3.3 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.1 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 3.0 | 3.3 | 2.7 | 2.1 |
| Other liabilities | 5.9 | 6.9 | 11.4 | 5.0 |
| Shareholders' equity | 53.1 | 81.8 | 124.7 | 95.4 |
| Net tangible assets | 53.1 | 81.8 | 124.7 | 95.4 |
AN2 Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -29,834,000.0 | -49,257,000.0 | -53,288,000.0 | -33,462,000.0 | — |
| Investing Activities | 28,311,000.0 | 54,589,000.0 | -43,278,000.0 | -21,771,000.0 | — |
| Financing Activities | 113,000.0 | 372,000.0 | 84,994,000.0 | 70,355,000.0 | — |